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This review addresses the initial stages of nonproliferative diabetic retinopathy in diabetes type 2.
The natural history of the initial lesions occurring in the diabetic retina has particular relevance for our understanding and
management of diabetic retinal disease, one of the major causes of vision loss in the western world. Diabetic retinal lesions are still
reversible at this stage opening entirely new opportunities for effective intervention.
Four main alterations characterize these early stages of diabetic retinopathy: microaneurysms/hemorrhages, alteration of the
blood–retinal barrier, capillary closure and alterations in the neuronal and glial cells of the retina. These alterations may be
monitored by red-dot counting on eye fundus images and by ﬂuorescein leakage and retinal thickness measurements.
A combination of these methods through multimodal macula mapping has contributed by identifying three different phenotypes
of diabetic retinopathy. They show different types and rates of progression which suggest the involvement of different susceptibility
genes. The identiﬁcation of different phenotypes opens the door for genotype characterization, different management strategies
targeted treatments.
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that eventually develops, to some degree, in nearly
all patients with diabetes mellitus. Diabetic retinopathy
is characterized by gradually progressive alterations in
the retinal microvasculature and is the leading cause
of new cases of legal blindness among Americans
between the ages of 20 and 74 years of age (Aiello
et al., 1998).
Diabetic retinopathy occurs in both type 1 (also
known as juvenile-onset or insulin-dependent dia-
betes) and type 2 (also known as adult-onset or
noninsulin-dependent diabetes) diabetes. All the fea-
tures of diabetic retinopathy may be found in both types
of diabetes but characteristically the incidence of the
main causes of vision loss, macular edema and retinal
neovascularization, is quite different for each type of
diabetes (Aiello et al., 1998). Diabetic retinopathy in
type 1 diabetes induces vision loss mainly due to
the formation of new vessels in the eye fundus
and development of proliferative retinopathy, whereas
in type 2 diabetes vision loss is most commonly due
to macular edema and proliferative retinopathy is
relatively rare.
It is apparent, from the data available from a variety
of large longitudinal studies, that the evolution and
progression of diabetic retinopathy vary according to
the types of diabetes involved, showing dissimilarities
among different patients even when belonging to the
same type of diabetes and does not necessarily progress
in every patient to proliferative retinopathy. We will
address in this review only the initial stages of
nonproliferative retinopathy in diabetes type 2.1. Present classiﬁcations of nonproliferative diabetic
retinopathy
There have been many attempts to classify the lesions
observed in the retina in diabetes. The ﬁrst such
classiﬁcation that resulted from consensus and was
accepted internationally was the Airlie House classiﬁca-
tion.
The Airlie House Classiﬁcation was developed by a
12-member committee during a Symposium on the
Treatment of Diabetic Retinopathy held at Airlie House
in Warrington, VA, in September 1968 (Goldberg and
Fine, 1969). The goal of its authors was to provide a
simple scheme for expressing the presence and severity
of the fundus lesions commonly seen in this disorder
that were suitable for ophthalmoscopy or fundus
photography.Like most other classiﬁcations of diabetic retino-
pathy, the early treatment diabetic retinopathy study
(ETDRS) (Early Treatment Diabetic Retinopathy Study
Research Group, 1991) modiﬁcation of the Airlie House
classiﬁcation is limited to assessing the severity and/or
extent of various characteristic abnormalities but does
not provide an overall severity scale and has been tested
solely for evaluation of progression to proliferative
diabetic retinopathy.
In the diabetic retinopathy study (DRS) (Diabetic
Retinopathy Study Research Group, 1981), a useful
deﬁnition was proposed for only one part of the picture,
the severe stage of nonproliferative diabetic retinopathy
(NPDR). In this deﬁnition, which was based on clinical
impression and quantitative clinical descriptions, four
abnormalities were considered: hemorrhages and/or
microaneurysms, cotton-wool spots (soft exudates),
intraretinal microvascular abnormalities (IRMA’s) and
venous beading. Additional DRS analyses demonstrated
that hemorrhages and/or microaneurysms and venous
beading were the more powerful predictors of visual
loss.
The ETDRS adopted the DRS deﬁnitions of severe
NPDR and contributed by deﬁning moderate NPDR in
a more detailed scale. It is interesting that these scales
and classiﬁcations were all based in a variety of complex
statistical analyses all focused on the percentage of
eyes with progression to proliferative diabetic retino-
pathy. The ETDRS-based classiﬁcation of severity and
progression of diabetic retinopathy is entirely based on
the assumption that the retinopathy is homo-
geneous and will ultimately progress to proliferative
retinopathy. Detailed information on the segment of the
ﬁnal scale dealing with mild-to-severe NPDR is related
to 1-, 3- and 5-year rates of proliferative diabetic
retinopathy.
The ETDRS research group in their Report number
12 clearly state that ‘‘because few eyes were included in
the ETDRS that had very mild retinopathy the
deﬁnitions of the ﬁnal scale regarding the lower range
of NPDR could not be examined’’ (Early Treatment
Diabetic Retinopathy Study Research Group, 1991).
For example, it could not determine whether presence of
mild retinal hemorrhages in addition to microaneurysms
was sufﬁciently less severe than the presence of hard or
soft exudates to merit designation of separate levels for
these two groups (i.e., division of level 35 into two
parts).
The available classiﬁcations of diabetic retinopathy
give very useful information but have two major
problems.
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the disease, which is clearly the most interesting stage
because it is the one that shows some degree of
reversibility and may respond to improved medical
treatment and new forms of treatment.
The second, is the fact that the ETDRS classiﬁcation,
which is considered the reference classiﬁcation, was
constructed on the basis that diabetic retinopathy, given
time, uniformly progresses to proliferative retinopathy.
It assumes that retinal neovascularization and prolif-
erative retinopathy are direct consequences of dia-
betes. There are, on the contrary, many arguments to
support the thesis that proliferative retinopathy
occurs in diabetes as a result of the extensive capillary
closure and ischemia and is, in itself, relatively
independent of the diabetic general metabolic status
(Cunha-Vaz, 1978).
Other classiﬁcations have been proposed recently in
an effort to simplify the ETDRS ﬁnal scale (Wilkinson
et al., 2003). Their goal has been to establish references
for clinical studies and to facilitate clinical follow-up of
diabetic retinopathy. They do not address the need for
more detailed characterization of initial stages of
diabetic retinal disease and therefore are not discussed
in this review.2. Natural history of the initial stages of NPDR
The fundus abnormalities that are identiﬁed on
clinical examination of mild to moderate NPDR include
microaneurysms and/or hemorhages, i.e., red-dots in the
fundus, and exudates.
The initial stages of NPDR are, therefore, character-
ized by the presence of red-dots (microaneurysms and/or
hemorhages) and indirect signs of vascular hyperme-
ability and capillary closure, i.e., both hard and soft
exudates or cotton-wool spots, respectively.
These are the alterations that dominate the initial
stages of NPDR and we will analyze their development
and progression, in order to clarify their relative
importance in the progression of diabetic retinopathy.
They are not present in every patient in the same way
nor at the same rate.
It must be realized that the course and rates of
progression of the retinopathy vary between patients.
Microaneurysms, for example, may come and go.
Once you get a microaneurysm you do not necessarily
continue to have that microaneurysm. Microaneurysms
may disappear due to vessel closure, which is an
indication of worsening of the retinopathy because
of progressive vascular closure (Cunha-Vaz, 1992).
Hemorrhages will obviously come and go as the
body heals them. Clinical improvement may be
apparent but in reality it masks the worsening of the
disease.A prominent feature of diabetic retinopathy, diabetic
macular edema, can spontaneously resolve itself. In-
deed, it is resolved in approximately a third of patients
over a period of 6 months, without any intervention.
(Ferris and Davis, 1990)
The initial pathological changes occurring in the
diabetic retina are characteristically located in the small
retinal vessels of the posterior pole of the retina, that is,
in the macular area. The structural changes in the small
vessels include endothelial cell and pericyte damage and
thickening of basement membrane (Cunha-Vaz, 1978;
Garner, 1987).
Normally, retinal vascular endothelium is a funda-
mental part of the blood–retinal barrier (BRB), which
has many similarities with the blood–brain barrier. It
functions as a selective barrier which has shown to be
altered in experimental and human diabetes (Cunha-Vaz
et al., 1975).
Pericyte damage has been reported as one of the
earliest ﬁndings in diabetic retinal disease since the
introduction of retinal digest studies (Cogan and
Kwabara, 1963). However, pericyte apoptosis is more
readily detectable than endothelial cell apoptosis, most
probably because the pericytes are encased in basement
membrane and thus, less accessible to clearing mechan-
isms, whereas apoptotic endothelial cells slough off into
the capillary lumen and are cleared by blood ﬂow.
The simplest paradigm that explains capillary perme-
ability and closure centers on the vascular endothelium.
In the retina, endothelial cells are the site of the BRB, a
speciﬁc blood-tissue barrier, and, as in all vessels,
provide a nonthrombogenic surface for blood ﬂow.
Both these properties are eventually compromised by
diabetes.
On the other hand, diabetes also affects the neural
and glial cells of the retina. Consequently, we have an
initial pathological picture characterized by endothelial
and pericyte alterations associated with basement
membrane thickening and microaneurysm formation.
These alterations are characteristic for the retina,
particularly the alteration of the BRB, the pericyte
damage and the microaneurysm formation, but occur in
a variety of diseases unrelated to diabetes. There is clear
site speciﬁcity, not disease speciﬁcity (Cunha-Vaz, 1978).
Which are then the features of the retinal circulation
which are speciﬁc to the retina and may be responsible
for the site speciﬁcity of diabetic retinopathy? They are
the BRB and the autoregulation of retinal blood ﬂow.
Both serve the needs of the neuronal and glial cells of the
retina.
An abnormality of the BRB, demonstrated both by
vitreous ﬂuorometry and ﬂuorescein angiography is an
early ﬁnding both in human and experimental diabetes
(Cunha-Vaz et al., 1975; Waltman et al., 1978a, b).
Fluorescein leakage is one of the earliest ﬁndings in
diabetic retinal disease, demonstrating the alteration of
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Fig. 1. Red-dot identiﬁcation by location in the macula in a 2-year
period of follow-up at the initial visit VS, 6 (V6), 12 (V12), 18 (V18)
and 24 (V24) month.
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which remains the most frequent cause of visual loss in
diabetes.
Another important characteristic of the retinal
circulation is its capacity to autoregulate and compen-
sate variations in blood pressure, ocular tension, etc.,
maintaining a relatively uniform blood ﬂow. Changes in
retinal blood ﬂow have, indeed, been reported in both
human and experimental diabetes (Kohner, 1977).
Capillary closure leading to retinal ischemia and
inducing neovascularization and proliferative retinopa-
thy, leads to the most tragic outcomes for visual loss:
vitreous hemorrhage, rubeosis iridis, retinal detachment,
etc. It is becoming apparent that at least three processes
can contribute to retinal capillary occlusion and
obliteration in diabetes: proinﬂammatory changes,
microthrombosis, and apoptosis (Gardner and Aiello,
2000). These processes have been documented in both
human and experimental diabetes. There are indications
taken from experimental studies that proinﬂammatory
changes and leukostasis are early events and that
microthrombosis and apoptosis occur subsequently.
2.1. Microaneurysms/hemorrhages. Red-dots formation
and disappearance rates
Microaneurysms (MA) and hemorrhages (HEM)
identiﬁed as red-dots are the initial changes seen on
ophthalmoscopic examination and fundus photography
(SFP). They may be counted and red-dot counting has
been suggested as an appropriate marker of retinopathy
progression (Klein et al., 1995a, b).
It must be realized that red-dot formation and
disappearance are dynamic processes. During a 2-year
follow-up of 24 type 1 diabetics with mild background
diabetic retinopathy using ﬂuorescein angiography,
Hellstedt and Immonen (1996) observed 395 new MA
and the disappearance of 258 previously identiﬁed.
Generally, the disappearance of a MA is not a
reversible process and indicates vessel closure and
progressive vascular damage. Therefore, to assess
progression of retinopathy, red-dot counting should
take into account every newly developed red-dot
identiﬁed in a new location.
We have developed software for assisted red-dot
counting in fundus-digitized images where the loca-
tion of each red-dot is taken into account and registered
(Fig. 1). In this way, in a follow-up study with repeated
fundus images obtained at regular intervals, all red-dots
in the fundus were counted and added as they became
visible in new locations in the retina. The results of red-
dot counting using this method, in a 2-year follow-up
study of a series of eyes with mild nonproliferative
retinopathy in subjects with type 2 diabetes maintaining
a stable metabolic control during the period of the study
suggest that red-dot counting may be a good marker ofdisease progression in the initial stages of NPDR
(Torrent-Solans et al., 2004).
Fifty eyes from 50 patients, with type 2 diabetes
mellitus and mild nonproliferative retinopathy, were
prospectively followed. These were consecutive patients
that fulﬁlled the inclusion criteria. Treated with oral
hypoglycemic agents, they maintained a stable meta-
bolic control.
One selection criterion was the presence of at least one
red-dot at the ﬁrst visit in ﬁeld 2 of the 7-ﬁeld stereo
fundus photography (SFP) assessed by two independent
readers.
Fundus photographs were taken every 6 months.
Field 2 (centered in the macula) was chosen for the
analysis of the presence of red-dots since this is the most
important area in terms of potential visual impairment.
In order to improve human grader reliability in the
identiﬁcation and counting of red-dots on color fundus
images, the software included algorithms for eye move-
ment compensation, color correction and identiﬁcation
of each red-dot by its coordinates.
Using the software’s ability to identify each red-dot as
a single entity, in a speciﬁc location with identiﬁable
coordinates, the following parameters were assessed:1. Cumulative number of red-dots. This number is
achieved using the main advantage of the new
software, its ability to consider each red-dot as a
single entity, identiﬁed by its speciﬁc location.
Therefore, a red-dot identiﬁed on a new location is
recognized as a new red-dot and added.2. Red-dot formation rate. Red-dot formation rate is
the annual rate of change over the study period. It is
computed dividing the difference of the cumulative
number of red-dots between the last and ﬁrst visits by
the 2 years period.3. Red-dot disappearance rate. Red-dot disappearance
rate is the sum of the red-dots that disappeared
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follow-up. A disappeared red-dot is one missing red-
dot from a previous visit that will not show up again
(during the study period).
Using the traditional procedure, the total amount of
red-dots detected at every visit remained stable. How-
ever, the cumulative number of red-dots raised from 115
at the ﬁrst visit to 505 at the last visit, showing a marked
increase in new red-dots. These ﬁgures emerged because
of the software’s potential for counting every red-dot as
a single entity once it was identiﬁed by its speciﬁc
location. It is now obvious that there were many more
red new dots in the fundus, i.e., microaneurysms and
small hemorrhages, in this 2-year time period than
expected using data for each examination separately.
One of the advantages of the method used is the
ability to count the number of real new red-dots
appearing at every visit (red-dot formation rate). The
rate of formation (red-dots/year) ranged from 0 to 22.
The results showed that eyes in the same retinopathy
stage from different patients show very different red-dot
formation rates. Values for red-dot formation rate
higher than 3/year correlated well with increased
ﬂuorescein leakage measured by vitreous ﬂuorometry
(po0:001) and capillary closure identiﬁed by a damaged
foveal avascular zone (FAZ) (po0:038), demonstrating
a direct correlation with faster retinopathy progression.
The rate of disappearance (red-dots per year) ranged
from 0 to 16. Red-dot disappearance rates also varied
quite markedly in eyes from different patients and
showed similar correlations.
In a recently developed International Clinical Dia-
betic Retinopathy Disease Severity Scale, developed
under the auspices of the American Academy of
Ophthalmology, the identiﬁcation of microaneurysms
and hemorrhages characterize the initial, mild stage, of
diabetic retinopathy (Wilkinson et al., 2003).
Microaneurysms and hemorrhages identiﬁed by fun-
dus photography as red-dots are considered the ﬁrst
clinical sign of retinopathy. Microaneurysm formation
has been associated with localized proliferation of
endothelial cells, loss of pericytes and alterations of
the capillary basement membrane, alterations that occur
in the initial stages of diabetic retinal disease and have
been considered to be directly involved in its pathophy-
siology (Ashton, 1963, 1974; Cunha-Vaz, 1978).
Microaneurysm closure and disappearance is most
probably due to thrombotic phenomena leading to
subsequent rerouting of capillary blood ﬂow and
progressive remodeling of the retinal vasculature in
diabetes (Boeri et al., 2001). These thrombotic changes
are probably enhanced by changes in the red and white
cells occurring as a result of diabetes. The presence and
number of microaneurysms and their rates of formation
and disappearance are, therefore, good candidates asmarkers of retinal vascular remodeling and may be good
indicators of retinopathy progression.
Red-dot counting on fundus photographies and
microaneurysm counting on ﬂuorescein angiography
have been proposed as predictive indicators for progres-
sion of diabetic retinopathy (Kohner et al., 1986). Our
specially developed software allows the identiﬁcation of
the exact location of each red-dot in successive fundus
photographs performed in each eye. Identiﬁcation of the
exact location of an individual red-dot is considered
particularly important because a new microaneurysm is
considered to develop only once in a speciﬁc location, its
disappearance being generally associated with capillary
closure, leaving in its place mainly remnants of base-
ment membrane (Ashton, 1974; Cunha-Vaz, 1978).
Our study demonstrated a steady turnover of red-dots
in the diabetic retina, even in the initial stages of
retinopathy. In fact, most red-dots show a lifetime of
less than 1 year, with new ones being formed and
disappearing at rates which vary between different
patients, conﬁrming previous reports (Kohner and
Dollery, 1970).
Most interestingly, however, is the observation that
some patients show much higher rates of red-dot
formation and disappearance, suggesting that they
may represent a speciﬁc phenotype of diabetic retino-
pathy. These eyes showed faster retinopathy progres-
sion, with increased ﬂuorescein leakage, i.e., alterations
of BRB, and shorter duration of diabetes.
Red-dot counting on fundus photography instead of
microaneurysm counting on ﬂuorescein angiography is
particularly promising because fundus photography is
noninvasive and well accepted by the patients, particu-
larly when involving repeated examinations.
In conclusion, our results, based on precise identiﬁca-
tion of the location of each red-dot on fundus
photograph of diabetic eyes, suggest that red-dot
formation and disappearance rates may be appropriate
indicators of retinopathy progression, identifying in this
simple way a diabetic retinopathy phenotype character-
ized by rapid retinopathy progression.
2.2. Alteration of the BRB. Fluorescein leakage
measurements
Since the early 1950s, two research groups have
contributed signiﬁcantly to our understanding of the
pathological picture of diabetic retinopathy: Ashton and
co-workers in London (Ashton, 1963) and Cogan and
his co-workers in Boston (Cogan and Kwabara, 1963).
From their observations the endothelial cells and the
pericytes were seen to be affected from the earlier stages
of diabetic retinopathy. When the BRB was found to be
located primarily at the level of the endothelial
membrane of retinal vessels (Shakib and Cunha-Vaz,
1966) it was only natural to assume that an alteration of
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retinal diseases. Ashton, in his 1965 Bowman Lecture,
stated that early lesions of diabetic retinopathy are
‘‘focal breakdowns of the BRB’’ (Ashton, 1965).
The advent of ﬂuorescein angiography conﬁrmed
most of what was known about the initial pathological
picture of diabetic retinopathy and showed in the initial
stages of the disease focal leaks of ﬂuorescein, demon-
strating, in a clinical setting, the existence of focal
breakdowns of the BRB.
In 1975, vitreous ﬂuorometry, a clinical quantitative
method for the study of the BRB, was introduced by our
group (Cunha-Vaz et al., 1975), showing that an
alteration of the BRB could be detected and measured
in some diabetic eyes with apparently normal fundi.
These results were conﬁrmed by Waltman et al. (1978b).
Thereafter, many experimental and clinical studies
have examined the alteration of the BRB in diabetes
with conﬂicting results at times, but showing in general
that an alteration of the BRB is present in the diabetic
retina and may have an important role in its develop-
ment and progression (Cunha-Vaz, 2000a, b).
The damaged capillaries leak their contents intrar-
etinally, resulting in the formation of hard yellow
exudates (conﬂuents of lipids and lipoproteins) in the
nerve ﬁber layer and edema. Localized hemorrhages also
result from the excessive vascular porosity. If present,
hemorrhages take the form of dots and blots, an
appearance attributable to their deep location and
sequestration of blood in an anatomically compact
retina.
Breakdown of the BRB plays, therefore, an important
initiating role in the development of the pathological
picture of diabetic retinopathy.
An alteration of the BRB has, indeed, been docu-
mented in a variety of studies using different models
of experimental diabetes. These studies, initiated by
Waltman and co-workers, (Waltman et al., 1978a)Fig. 2. Vitreous ﬂuorophotometry recording from an eye with
nonproliferative retinopathy from a patient with diabetes type 2
obtained 1 h after intravenous ﬂuorescein injection. Note the
ﬂuorescence curve in the vitreous across an altered BRB. Reference
landmarks: R-retina; C-cornea.showed an alteration of the BRB in rats with
streptozotocin-induced diabetes, well demonstrated
by vitreous ﬂuorometry, soon after the induction of
chronic hyperglycemia. Futhermore, this alteration of
the BRB was reversed by the administration of insulin
and regularization of glycemia.
The alteration of the BRB in the rat with streptozo-
tocin-induced diabetes occurs only 1 week after the
administration of streptozotocin. There have been,
however, contradicting reports regarding this site of
the BRB breakdown. Studies using horseradish perox-
idase as a tracer for electron microscopic investigation,
pointed to the retinal pigmented epithelium as the main
structure affected (Tso et al., 1980). However, studies
using histochemical localization of naturally occurring
albumin, performed by Murata et al. (Murata et al.,
1993) and Vin˜ores et al. (Vin˜ores et al., 1990) have
clearly shown that the main site of increased perme-
ability of the BRB is located at the level of the inner
BRB involving the retinal vessels. More recently, our
group in Coimbra have demonstrated using confocal
microscopy that the breakdown of the BRB occurring in
rats 1 week after onset of streptozotocin-induced
diabetes is localized preferentially in the inner BRB
(Carmo et al., 1998).
In alloxan-induced diabetes, Engerman was able to
demonstrate in the dog the development of a retino-
pathy presenting many of the features seen in man
(Engerman, 1976). Ultrastructural studies, using horse-
radish peroxidase, a relatively large protein, demon-
strated breakdown of the BRB in eyes showing signs of
microvascular alterations. The breakdown of the inner
BRB was manifested by the presence of the tracer in the
cytoplasm of the endothelial cells and in ruptured
junctions. It is noteworthy that the breakdown of the
BRB was observed preferentially in vessels showing
signs of endothelial proliferation.
Clinical studies on the application of vitreous
ﬂuorometry to diabetes were reported for the ﬁrst time
in 1975 (Cunha-Vaz et al., 1975). The examination of a
series of predominantly adult-onset diabetics with
apparently normal fundi revealed the frequent presence
of an alteration of the BRB. The ﬂuorescein concentra-
tion curves in the vitreous in the diabetic patients
followed a gradient indicating penetration of ﬂuorescein
across the BRB (Fig. 2).
During the following years many research efforts were
directed at improving the instrumentation and standar-
dization of the method. An ocular ﬂuorometer described
by Zeimer et al. ﬁnally became available commercially,
thus making it possible to repeat studies at different
centers avoiding much of the variability in instrumenta-
tion that played some of the earlier studies (Zeimer et
al., 1983).
An European multicenter study involving six different
research groups showed that vitreous ﬂuorometry,
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well-deﬁned protocol, is a highly sensitive and reliable
method for measuring the permeability of the BRB (Van
Schaik et al., 1997).
Values for the BRB permeability coefﬁcient obtained
by different authors have shown good agreement. The
European Community Network of Ocular Fluorometry
found a mean value of 1.9770.93 107 cm/s on data
collected from six centers for a total of 81 healthy
volunteers.
A general review of the many studies performed using
vitreous ﬂuorometry, in both type 1 and 2 diabetes,
shows that there is, in both types of diabetes, an
alteration which is always present after development of
ophthalmoscopically visible retinopathy and present in
some eyes even before the development of clinically
visible retinopathy (Cunha-Vaz et al., 1986). This
breakdown of the BRB increases with duration of the
disease and is associated with poor metabolic control.
We have followed in a 7-year prospective follow-up
study a group of 40 patients with adult-onset diabetes
mellitus, with retinopathy no greater than level 35 of the
modiﬁed Airlie House Classiﬁcation of diabetic retino-
pathy at the commencement of the study (Cunha-Vaz et
al., 1998). They were examined by fundus photography,
ﬂuorescein angiography and vitreous ﬂuorometry, at
entry into the study and 1, 4 and 7 years after the initial
examination. After 7 years follow-up a total of 22 of the
40 eyes had received photocoagulation. The eyes that
needed photocoagulation were those that had higher
vitreous ﬂuorometry values at entry to the study and
showed higher rates of deterioration. Abnormally high
vitreous ﬂuorometry values and their rapid increase over
time were shown to be good indicators of progression
and worsening of the retinopathy with need for
photocoagulation.
Similar ﬁndings have been reported by Engler et al. in
an 8-year follow-up study of type 1 diabetic patients
(Engler et al., 1991). Initially, the patients were
submitted to fundus photography and vitreous ﬂuoro-
metry for determination of the BRB permeability. After
8 years the patients were re-examined. A positive
correlation between a high initial permeability value
and an unfavorable clinical course, using photocoagula-
tion as the outcome parameter, was found. In summary,
in patients showing the same retinal morphology, high
permeability of the BRB indicates a particular pheno-
type characterized by an unfavorable course of disease
(Waltman, 1989).
It appears, therefore, that an alteration of the BRB,
measured by vitreous ﬂuorometry, is an early ﬁnding in
diabetic retinal disease and correlates well with progres-
sion and worsening of the retinopathy.
One major limitation of the available commercial
instrumentation for V.F. was associated with the fact
that the permeability of the BRB is measured as anaverage over the macular area. Accurate mapping of
localized changes in the permeability of the BRB would
be beneﬁcial for early diagnosis, to explain the natural
history of retinal disease, and to predict its effect on
visual acuity.
We have recently developed a new method of retinal
leakage mapping, the retinal leakage analyzer (RLA),
that is capable of measuring localized changes in
ﬂuorescein leakage across the BRB while simultaneously
imaging the retina (Fig. 3). The instrument is based on a
confocal scanning laser ophthalmoscope that was
modiﬁed into a confocal scanning laser ﬂuorometer
(Lobo et al., 1999).
Two types of information are obtained simulta-
neously, distribution of ﬂuorescein concentration (retina
and vitreous) and fundus image. This simultaneous
acquisition is crucial because it allows a direct correla-
tion to be established between the maps of permeability
and the morphological information.
It is now possible to follow the natural history of focal
alterations of the BRB occurring in the initial stages of
the disease and to identify their location and measure
the changes over time, while examining their association
with the main morphological changes occurring in the
diabetic retina, such as microaneurysms, capillary
closure and retinal edema.
2.3. Retinal blood flow and capillary closure
Retinal ischemia due to vascular closure develops
relatively early in the course of diabetic retinopathy and
is attributed to changes in vascular autoregulation and
microthrombosis formation. Retinal blood ﬂow changes
are considered to lead to the development of poor
perfusion facilitating microthrombosis formation (Boeri
et al., 2001).
The control of blood ﬂow through the retina depends
on changes in the ophthalmic artery caliber (which has
sympathetic innervation) or humoral and local factors.
Retinal vessels have no sympathetic nerve supply
(Malmfors, 1965). Therefore, local factors play a
dominant role. Retinal vessels are particularly respon-
sive to changes in arterial pO2 and to a lesser extent, to
changes in pCO2 (Kohner et al., 1975; Kohner, 1977).
The response to altered demand by the tissues is
mediated through the ‘‘autoregulatory’’ adaptation of
the blood vessels and blood ﬂow.
Alterations in retinal blood ﬂow have been identiﬁed
in the different stages of the progression of retinopathy.
In patients with mild retinopathy and using a two-point
ﬂuorophotometry technique, we found an increase in
retinal arteriolar velocity (Cunha-Vaz et al., 1978). This
ﬁnding was conﬁrmed by Cuypers et al. (2000) using
laser Doppler ﬂowmetry. Other authors have, however,
registered a decrease in retinal blood ﬂow. Sullivan and
associates (Sullivan et al., 1990) found reduced blood
ARTICLE IN PRESS
Fig. 3. Macula from a patient with diabetes type 2. Left: ﬂuorescein angiography obtained by scanning laser ophthalmoscope. Right: retinal leakage
analyzer BRB permeability map (Rlmap) in a false color-code map. Two-concentric circles of 100 and 750 mm radii centered on the fovea are shown
on the ﬁgure. Note that not all hyperﬂuorescent areas in the left picture correspond to sites of increased ﬂuorescein leakage into the vitreous, well
depicted in the right.
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increasing only in association with high glucose levels.
In more advanced stages of retinopathy, the results also
conﬂict, with some authors reporting decreases in retinal
blood ﬂow (Michelson et al., 2001) and others reporting
increases (Bursell et al., 1996).
One of the major problems associated with these
measurements is their technical complexity and varia-
bility.
Cuypers et al. (2000) used the Heidelberg Retina
Flowmeter (HRF; Heidelberg Engineering, Dossen-
heim, Germany) on a series of eyes from patients with
either type 1 or type 2 diabetes. They included in the
study patients with all grades of retinopathy. They
considered the methodology to be reliable.
We have examined with the HRF a series of eyes
without clinical signs of retinopathy of subjects with
type 2 diabetes and compared our ﬁndings with a
control healthy population, after examining the repro-
ducibility of the different softwares available and
different examination methodologies (Ludovico et al.,
2003).
We have, in this study, used the HRF, realizing that
this technique is technically restricted to perform reliable
measurements of blood ﬂow in small vessels of the
retinal capillary superﬁcial layers. Retinal capillary
blood ﬂow measurements performed in the papilloma-
cular area using the whole-scan analysis and the
automated full-ﬁeld perfusion image analysis proposed
by Michelson et al. (1998) showed acceptable reprodu-
cibility in both healthy and diabetic eyes. This metho-
dology involves automatic subtraction of large vessels
and takes into account the heartbeat associated pulsa-
tion, artiﬁcial movements and local variations in
brightness of the fundus.
When comparing the retinal capillary blood ﬂow
measurements obtained from the papillomacular area
with the HRF using the automated full-ﬁeld perfusionimage analysis method in diabetic eyes with preclinical
retinopathy and healthy control eyes, the retinal blood
ﬂow was increased in the diabetic eyes. However, when
analyzing the results obtained in each eye it became clear
that this increase in retinal blood ﬂow varied markedly
between different patients. Five of the 10 diabetic
patients showed clearly abnormal increases in retinal
capillary blood ﬂow, i.e., with four of them presenting
values higher than the mean +2SD of the values
registered for all parameters (volume, ﬂow and velocity)
in the normal control group. The other ﬁve diabetic
patients showed values within the normal range.
These ﬁndings may have particular relevance. They
may explain the conﬂicting reports in the literature and
indicate that changes in retinal capillary blood ﬂow are
an early alteration in the diabetic retina but do not occur
in the same degree or at the same time in every retina.
They may develop as a result of other retinal alterations
and may be of particular value by identifying the eyes
that are at risk for progression of the retinopathy and
this way indicating different phenotypes of diabetic
retinopathy.
In this study, the increases in retinal capillary blood
ﬂow registered in 5 of the 10 diabetic eyes with
preclinical retinopathy did not show any clear correla-
tions with level of metabolic control (HbA1C), blood
glucose values on the day of the examination, duration
of the disease, blood pressure levels or other systemic
variables, in agreement with the observations of Cuypers
et al. (2000).
There are several possible explanations for an increase
in capillary blood ﬂow in diabetes (Kohner et al., 1975).
It could indicate shunting, an increase in capillary
diameter or capillary recruitment.
The ﬂow of red blood cells through retinal capillaries
is modulated by intravascular and extravascular factors.
The intravascular pressure gradient between the pre-
capillary arteriole and the postcapillary venule is
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ﬂow. In this study, all patients with type 2 diabetes had
similar and acceptable levels of blood pressure. On the
other hand, an increase in capillary diameter is
considered to have a relatively small effect on the
pressure gradient and, therefore, results in a small
decrease in capillary ﬂow. Shunting phenomena or
capillary recruitment are the most likely candidates to
explain the marked increase in capillary red blood cell
ﬂow observed in ﬁve of the 10 eyes of patients.
It is thought that under normal physiological condi-
tions most retinal capillaries are perfused by both
plasma and red blood cells. Fluorescein angiographic
studies indicate that retinal capillaries are continuously
perfused. However, the ﬂuorescein method does not
distinguish between ﬂow of plasma and ﬂow of plasma
and red cells together.
It is accepted, that in the brain, in a small fraction of
capillaries, red blood cell perfusion may stop for brief
periods—not longer than a few seconds—indicating
some degree of intermittence of red blood ﬂow in the
capillaries, i.e., plasma skimming.
Whether capillaries open and close at rest, and during
adaptation of capillary blood ﬂow to changing meta-
bolic needs, is still a matter of controversy. Functional
‘‘thoroughfare channels’’ or preferential capillaries with
high resting ﬂow have been proposed to play a central
role in microcirculation of the brain, surrounded by
other capillaries, characterized by slow resting ﬂow
which could be recruited when the tissue blood supply is
challenged (Hasegawa et al., 1967).
Finally, another possible alternative is that in the
retinal capillaries plasma ﬂow is continuous but red cells
travel through only some capillaries at all times. In this
case, capillary recruitment would be a natural response
to increased metabolic demands by the retinal tissue in
diabetes (Kageman et al., 1999) or a situation of relative
hypoxia as proposed for the diabetic retina (Keen and
Chlouverakis, 1965).
It is possible that the eyes which show increased
capillary blood ﬂow, thus apparently creating condi-
tions for more rapid and progressive damage of the
capillary walls are at a special risk of progression to
retinopathy.
In this pilot study, there were no apparent correla-
tions between the capillary blood ﬂow alterations and
the metabolic alteration of the diabetic patients at the
time of the examination. This observation suggests that
the capillary blood ﬂow alterations registered are not
acute and transitory but may indicate a more permanent
status of the retinal circulation and characterize a
speciﬁc retinopathy phenotype, which appear to be
independent of age, metabolic control or duration of
diabetes.
Our observations indicate that in some diabetic eyes,
even before the development of visible retinopathy,there is (probably due to local factors) a marked
increase in retinal capillary blood ﬂow with the maximal
utilization of the retinal capillary net, whereas others do
not show this circulatory response.
This increase in blood ﬂow may contribute to
endothelial damage and establish the appropriate
conditions for microthrombosis formation.
In diabetes, plasma constituents are also affected and
red cells may be altered. Changes in blood viscosity
increase the chances of microthrombosis formation,
vessel damage and capillary closure.
Through abnormalities in clotting and the ﬁbronolytic
system in diabetes play certainly a role in retinal
capillary closure it is unlikely that they initiate the
process of diabetic retinal vasculature disease. The
posterior pole of the retina is affected initially in
diabetes in clear contrast to the peripheral involvement
which characterizes the retinopathies resulting from
blood disorders, like sickle-cell disease, macroglobuli-
nemia and multiple myeloma (Cunha-Vaz, 1978).
2.4. Neuronal and glial cells changes. Retinal thickness
measurements
We have stated previously that the simplest paradigm
to explain increased capillary permeability and the
advent of capillary closure centers on vascular endothe-
lium and pericytes. There are, however, a number of
reports showing changes in the neuronal and glial cells
of the retina in diabetes very early in the course of the
disease (Lorenzi and Gerhardinger, 2001). This is clearly
of major potential importance and it may indicate at
least a contributory role in the development of the
microangiopathy.
Reports of electroretinographic changes in diabetic
patients with demonstrable vascular lesions date back to
the 1960s and have been conﬁrmed by several authors
(Ghirlanda et al., 1997) who found the electroretino-
graphic abnormalities to originate in the ganglion and
inner nuclear layers. Studies mostly performed in
streptozotocin-induced diabetic rats have identiﬁed
changes in the neuroglial elements of the inner two-
thirds of the retina. Whether the neuroglial abnormal-
ities induced by diabetes eventually contribute to the
development of vascular pathology is still not known at
present.
Hard and soft exudates are frequent components of
the clinical picture of diabetic retinopathy. They are
considered to result from increased vascular perme-
ability and capillary closure but are deﬁnitely associated
with neuronal and glial damage.
In the rat retina, most of the neurons containing
neuronal nitric oxide synthase (NOs) appear to be from
amacrine cells which are closely related to the retinal
vasculature. The number of these n-NOs containing cells
was found to decrease by 32% as early as 1 week after
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reduced availability of nitric oxide may play a role by
inducing localized changes in blood ﬂow. Such altera-
tions may also be compounded by increased endothelin-
1 and endothelin-3 levels, which have been observed in
the neural cells of the inner retina 2–4 weeks after STZ-
diabetes (Deng et al., 1999). It is noteworthy that
increased endothelin levels may be induced by high
glucose through activation of protein kinase C (PKC)
(Takagi et al., 1996).
In the retina of diabetic rats another major alteration
observed only 1 month after STZ-diabetes is a 10-fold
increase in the frequency of apoptosis (Takagi et al.,
1996). The majority of apoptotic cells appeared to be
ganglion cells.
Although the extent of abnormalities in the neural
retinal cells in human diabetes appears to be less
conspicuous, there is also clear evidence of their
occurrence.
Namely, the phenomenon of early neuroretinal
apoptosis appears to be less prominent in human
diabetes than in the STZ-diabetic rats. However, the
issues of early and extensive neural apoptosis in human
diabetes and whether it precedes microangiopathy
remain to be settled.
Regarding the involvement of the glial cells in
diabetes there is also a wealth of information. Both
Muller cells and astrocytes envelope neurons the initial
segments of the ganglion cell axons, and blood vessels.
Speciﬁcally, the inner layer of retinal capillaries is
enveloped by both astrocytic and Muller cell processes,
while only the latter provide most of the glial wrapping
to the outer layer of the retinal vasculature (Holla¨nder
et al., 1991).
Muller cells have, indeed, characteristics that make
them potential targets of diabetes and potential con-
tributors to retinopathy. Muller cells are the primary site
of glucose uptake and phosphorylation in the retina
(Poitry-Yamate et al., 1965). They are endowed with
Glut1 and metabolize glucose intensely through glyco-
lysis to produce lactates that fuel neuronal metabolism
and are the primary site of glycogen storage and
metabolism in the retina. Muller cells are also primarily
involved in the transformation of glutamate in the retina
and in the acquisition of barrier properties by the
endothelial cells of the BRB.
Recent evidence suggests that retinal glial, and Muller
cells in particular, are affected early in the course of
both experimental and human diabetes. There are
reports demonstrating increased expression of glial
ﬁbrillary acidic protein (GFAP) and reduced ability to
convert glutamate into glutamine in diabetic rat retinas.
Glutamate excitotoxicity may occur in the diabetic
retina as a consequence of Muller cell dysfunction (Lieth
et al., 1998). It is still a matter of controversy if these
changes are preceded by an increase in capillarypermeability (Rungger-Bra¨ndle et al., 2000) and the
early alteration of the BRB.
It is interesting to note that the overexpression of
GFAP appears to be selective and is not likely to reﬂect
an increased number of Muller cells.
Thus, in both human and experimental diabetes, the
circumstances of increased retinal GFAP point to
altered regulation of gene expression. This could be
due to selective transcriptional effects of high glucose or
other metabolic abnormalities on the GFAP gene, or be
an element of more generalized changes in Muller cells
ﬁelding a speciﬁc ‘‘reactive’’ phenotype.
Diabetic macular edema is an important alteration
occurring in the initial stages of diabetic retinal disease.
Its importance is due to its association with loss of
vision. Based on WESDR data, it was estimated (as of
1993) that of approximately 7,800,000 people with
diabetes about 84,000 North Americans would develop
proliferation retinopathy and about 95,000 would
develop sight loss from macular edema over a 10-year
period (Klein et al., 1995a, b).
Edema of the retina is any increase of water of the
retinal tissue resulting in an increase in its volume, i.e.,
because of the structural organization of the retina, an
increase in its thickness. Macular edema is, therefore,
edema of the retinal tissue located in the macular area.
This increase in water content of the retinal tissue may
be initially intracellular or extracellular. In the ﬁrst case,
also called cytotoxic edema, there is an alteration of the
cellular ionic exchanges with an excess of Na+ inside the
cell. In the second case, also called vasogenic edema,
there is predominantly extracellular accumulation of
ﬂuid directly associated with an alteration of the BRB
(Cunha-Vaz and Travassos, 1984).
The clinical evaluation of macular edema has been
characterized by its subjectivity. Direct ophthalmoscopy
may show only an alteration of the foveal reﬂexes.
Stereoscopic fundus photography and slit-lamp biomi-
croscopy play an important role demonstrating changes
in retinal volume in the macular area but they are
dependent on the observer experience and the results do
not offer a true measurement of the volume change.
Furthermore, the interpretation of the extent and type
of macular edema varies markedly between different
observers (Kylstra et al., 1999).
Recently, new techniques have become available that
measure objectively retinal thickness.
Optical imaging instruments, like the retinal thickness
analyzer (RTA, Talia Technology, Ltd,) and optical
coherence tomography (OCT, Humphrey Instruments),
have been proposed as powerful tools for the objective
assessment of macular edema. Both techniques, which
are able to measure retinal thickness and rapidly
generate thickness maps at the posterior pole, are
noninvasive and noncontact procedures. Another in-
strument, the Heidelberg retina tomograph (HRT,
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scope that is able to measure retinal edema indirectly by
performing a topographic assessment of an unevenly
raised ‘‘retina’’ thus offering a map of relative increases
in retinal thickness (Ang et al., 2000).
The RTA is a quantitative and reproducible method
to evaluate retinal thickness. The variability in the
measurements obtained in normal subjects was reported
as 8% by Shahidi and co-workers (Shahidi et al., 1990).
The principle of the RTA is based on projecting a thin
He–Ne laser (543 nm) slit obliquely on the retina and
viewing it at an angle. The separation between the
reﬂections (and scatter) from the vitreoretinal interface
and the chorioretinal interface is a measure of the retinal
thickness. On the other hand, OCT provides cross-
sectional tomographs of the retinal structure in vivo, in
which optical interferometry is used to resolve the
distances of reﬂective structures within the eye.
Low coherence light from a superluminescent diode
source, operating at 840 nm (infrared light), is divided
into two beams: one incident on the retina and the other
incident on a translating mirror. The two reﬂected
beams, one on the mirror and the other on retinal
structures, are recombined and optical interference
detected by a photodiode.
The reproducibility of the method in normal subjects
was reported as 7% by Ang and co-workers (Ang et al.,
2000).
In recent studies performed with the RTA and OCT,
we chose to compare 5 regional measurements of retinal
thickness (Pires et al., 2002).
Two normal populations volunteered to participate as
age matched control groups for RTA and OCT and
reference maps were computed using the mean + 2SD.Fig. 4. The RTA and OCT identify well the retinal edema outlined by
stereofundus photography. Numbers in black correspond to %
increases in retinal thickness obtained using the RTA, whereas
numbers in green represent % increases in retinal thickness obtained
with OCT.Measurements of retinal thickness obtained with the
RTA or the OCT which were higher than the ones in
these reference maps were expressed as % increases over
the reference normal values (Lobo et al., 2000).
We examined three groups of eyes from subjects
with diabetes type 2: (1) with preclinical retinopathy;
(2) with mild to moderate nonproliferative retinopathy;
(3) with mild clinically signiﬁcant macular edema
according to the ETDRS guidelines, edema identiﬁed
by stereofundus photography.
In group 1, RTA detected abnormal increases in 86%
of the diabetic eyes examined, with increases ranging
from 0.3% to 73.5% over the normal mean value +
2SD. OCT detected retinal thickness increases in only
11% of the same series of eyes.
This study showed that there are localized areas of
retinal edema, i.e., areas of abnormal increase in retinal
thickness, occurring in the macula in the initial stages of
diabetic retinal disease. The RTA, in this study,
appeared to be able to detect localized increases in
retinal thickness in the diabetic retina well before OCT.
Comparable results have been reported by Shahidi
et al. (1991) and Hee et al. (1998). Shahidi et al. (1991)
observed that stereofundus photography did not identi-
fy locations with mild or localized thickening demon-
strated by the RTA. Hee et al. (1998) using the OCT
only detected increases in foveal thickness in 3.6% of a
series of 55 eyes with no visible retinopathy.
In another group of patients, with mild to moderate
nonproliferative diabetic retinopathy, the RTA detected
again larger increases, reaching values as high as 56.5%
and 73.5% over the normal value + 2SD in eyes graded
20 and 35 of the Wisconsin grading scale, respectively. It
was also clear from this study that the presence of
localized areas of retinal edema identiﬁed by the RTA is
not a constant ﬁnding in the diabetic retina, as a number
of eyes, 14%, remained edema-free. It is to be noted that
no clear correlation could be found between the extent
of the edema and the retinopathy grading, at least in
these initial stages of the retinopathy.
In the third study, we examined with the RTA and
OCT a series of eyes of patients with diabetes type 2
presenting clinically signiﬁcant macular edema as
deﬁned by stereofundus photography according to
ETDRS characteristics (Fig. 4).
In the central macula, the RTA measured increases in
retinal thickness higher than the mean + 2SD of a
healthy control population in 21 of the 25 eyes with
CSME characteristics (84%). There were, therefore,
four eyes with a diagnosis of retinal edema on
stereofundus photography which did not show increases
in retinal thickness with the RTA. These four eyes,
however, showed, the presence of isolated hard exu-
dates, conﬁrming the recent observations of Storm et al.
(2002) indicating that the presence of hard exudates may
mislead fundus photography graders into assuming the
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excluded, the RTA detected increases in retinal thick-
ness in 21 of the 21 eyes (100%) identiﬁed by fundus
photography, whereas the OCT measured increases in
retinal thickness in only 12 of the 21 eyes that had
edema identiﬁed by fundus photography in the central
macular area (57%). These ﬁndings are in agreement
with the observations of Zeimer (1998) who reported an
agreement of 78% between the RTA and stereophoto-
graphy, with disagreements generally associated with the
presence of hard exudates.
The eyes included in this study had characteristically
good visual acuity and belonged to the category of
relatively mild CSME. The OCT examination did not
show in any of these eyes, the presence of cyst-like
structures, large collections of ﬂuid or signs of dis-
organization of the retinal structure, thus conﬁrming the
mild nature of the retinal edema.
Measurements of retinal thickness are particularly
promising because of their quantitative nature and
provision of permanent records of the location and
degree of thickening.
Comparing the two techniques to measure retinal
thickness, the RTA appears to be particularly appro-
priate to measure changes in retinal thickness in eyes
with clear media and when these changes are minimal.
We consider it to be an extremely promising tool in
evaluating quantitatively the changes in retinal thickness
before the development of cystoid macular edema, and
when an early therapeutic intervention may be more
effective. OCT, on the other hand, uses a unique cross-
sectional scanning mode offering highly accurate ana-
tomic representation of the retina, which is particularly
useful when the retinal edema is associated with other
pathologies. OCT, in our experience, is particularly
informative when there are changes in the retinal
architecture, namely through the formation of cyst-like
spaces due to localized intraretinal ﬂuid accumulation,
or vitreous fraction is suspected. OCT is also to be
preferred when there is some degree of cataract
formation or the eyes have an implanted intraocular
lens.
In our experience both methods are well accepted by
the patients and can be performed with little discomfort,
giving reliable quantitative information on the size and
location of macular edema.
Measurements of retinal thickness offer an objective
evaluation of retinal edema and show that localized
areas of retinal edema are a frequent ﬁnding in the
diabetic retina in the initial stages of nonproliferative
retinopathy in subjects with diabetes type 2.
It is still not clear, however, if the retinal edema
occurring in the initial stages of diabetic retinopathy is
mainly vasogenic, due to the BRB alteration and what is
the relative role played by cytotoxic damage of the
neuronal and glial cells of the retina.2.5. Multimodal macula mapping
The initial changes occurring in the diabetic retina
involve the macula and an alteration of the macula will,
sooner or later, affect visual acuity. Diabetic macular
edema is a major contributor to visual loss because of its
preferential location to the macula. Characterization of
alterations occurring in the macula since their earliest
stages is, therefore, absolutely fundamental to follow
disease progression and preserve good visual acuity in
diabetes.
There are a variety of diagnostic tools and tech-
niques to examine the macular region and to obtain
information on its structure and function. The
different methods available offer different pers-
pectives and fragmentary information. It has been
our objective, in recent years, to combine different
methodologies and to obtain maps of the alter-
ations occurring in the macular region of the
retina.
Detection devices for obtaining information for
macula mapping are numerous and varied, often
complementing one another with differing degrees of
invasiveness, accuracy and object of measurement.
Some chart anatomy whereas others measure an aspect
of physiology. Together, they can combine structure and
function. Our research group has been developing
methods to combine and integrate data from fundus
photography, angiographic images (scanning laser
ophthalmoscope—ﬂuorescein angiography), maps of
ﬂuorescein leakage into the vitreous (scanning laser
ophthalmoscope—retinal leakage analyzer), maps of
retinal thickness and maps of visual function (auto-
mated perimetry—humphrey ﬁeld analyzer HFA II 750)
of the macular area to achieve multimodal macula
mapping (Lobo et al., 1999, 2000; Bernardes et al.,
2002). Scanning laser ophthalmoscopy (SLO) produces
high-resolution images using much less light for
illumination of the fundus than used for conventional
photography. High contrast images of the foveal and
perifoveal structures are produced with this technique
using directly reﬂected light. In confocal scanning laser
ophthalmoscopy (CSLO), a laser beam illuminates an
area of the eye fundus. A confocal stop placed in front
of the detector rejects most of the light coming from
both anterior and posterior planes. A set of moving
mirrors allows the scanning of an area of interest. In
SLO imaging, a laser beam illuminates an area of the
ocular fundus, forming a rectangular pattern (raster) on
the retina. The light reﬂected from each retinal point is
captured by the detector. Thus, a point-by-point video
image is constructed, with each retinal point corre-
sponding to a point on the monitor screen. SLO,
because of its monochromatic wavelength emission,
minimizes scattering and chromatic aberration. This
feature of SLO increases contrast and improves visibility
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Fig. 6. This multimodal image shows the integration of morphology,
blood ﬂow, thickness, leakage, visual function and OCT cross-section
image as a stack of images. The top image contains information on
morphology and ﬂow measurements. The second shows thickness
changes and identiﬁes leaking sites. The third represents visual ﬁeld
changes. Finally, in the bottom, the OCT cross-sectional image.
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photography.
SLO can also be used to perform high-resolution
ﬂuorescein angiographies. The contrast of the image
allows acquisition of high-quality morphological infor-
mation on the retinal vasculature. A system combining
SLO with Doppler ﬂowmetry provides noninvasive
evaluation of regional blood ﬂow. We have been able
to develop the retinal leakage analyzer, for measuring
and mapping the permeability of the BRB based on
CSLO system (Lobo et al., 1999). The combination of
two data sets, angiographic and permeability mapping,
obtained simultaneously using the same instrumenta-
tion, provided a good deﬁnition of landmark references
of the macula, giving simultaneously functional and
morphological information, and in this way was an
important step in the development of multimodal
mapping.
To integrate the information form the above sources,
a common reference has to be established. The reference
fundus image may be given by the RLA or by fundus
digital images, when using the RLA. To compute the
center of the fovea, the image is compressed with a LOG
function. This produces an image with a marked
difference between the FAZ and the remaining image.
A cross-correlation function is computed between the
compressed image and a 2D Gaussian function. The
result allows the determination of the center of the
fovea, since the shift in the maximum of the cross-
correlation to its center equals the shift of the center of
the fovea to the center of the fundus image.
We have been able to combine in multimodal macula
mapping, information on structure and function by
integrating data from ﬂuorescein angiography, retinal
leakage analysis (Fig. 5), and retinal thickness analysis.
Other available detection devices that may be used for
macula mapping include laser Doppler retinal ﬂowmetry
using the Heidelberg Retina Flowmeter, indocyanineFig. 5. Multimodal macula mapping of an eye with mild NPDR showing loc
represents the leakage using a false color-code. Units are  107cm s1 . Perc
density. Lines in white represent equal percentage of increase in thickness. Bla
represent increased retinal thickness. Percentages of increase are represente
squares. Percentages of increased leakage are represented by numbers in the
radii centered on the fovea.green angiography (ICG), electrophysiology (ERG),
autoﬂuorescence mapping and OCT (Fig. 6). Each one
of these methods adds more information and appears as
potentially valuable tools for evaluating the structure
and function of the retinal macula.
When examining diabetic macular edema, OCT and
HRF methodologies become particularly interesting
especially when the diabetic macular edema is associated
with some degree of vision loss. The HRF appears to be
particularly useful and reliable to follow changes in
capillary perfusion in the macular area and we arealized increases in leakage and retinal thickness. Left: the background
entage of increased thickness is represented in white dots with varying
ck lines and dots represent the retinal vasculature. Right: the gray areas
d in bold and intersecting lines. Each value represents four adjacent
squares. Also represented are two concentric circles of 100 and 750 mm
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ischemia.
Electrophysiological methods have been recently
proposed for retinal mapping with the introduction of
the multifocal electroretinography (mERG). The multi-
focal ERG technique was developed by Sutter (2001)
and can produce 100 or more focal responses from the
cone-driven retina. The display usually contains either
61 or 103 hexagons, although 241 hexagons have been
used in a few experiments to obtain higher spatial
resolution. With the 103 elements display, there is no
guarantee that a hexagon will fall entirely within the
optic disc. With a display of 241 elements, at least one
hexagon should fall entirely within the disk if steady
ﬁxation is maintained. In conclusion, the mERG
method offers attractive information on the electrical
functions of the retina, but improved spatial resolution
is necessary for useful macula mapping.3. Characterization of retinopathy phenotypes
It is well recognized that duration of diabetes and
level of metabolic control are major risk factors for
development of diabetic retinopathy.
However, these risk factors do not explain the great
variability that characterizes the evolution and rate of
progression of the retinopathy in different diabetic
individuals. There is clearly great individual variation
in the presentation and course of diabetic retinopathy.
There are many diabetic patients who after many years
with diabetes never develop sight-threatening retinal
changes, maintaining good visual acuity. There are also
other patients that even after only a few years of
diabetes show a retinopathy that progresses rapidly and
does not respond to laser photocoagulation treatment.
We have recently performed a prospective 3-year
follow-up study of the macular region, in 14 patients
with type 2 diabetes mellitus and mild nonproliferative
retinopathy, using multimodal macula mapping (Lobo
et al., 2004).
In a span of 3 years, eyes with minimal changes at the
start of the study (levels 20 and 35 of ETDRS-Wisconsin
grading) were followed at 6-month intervals in order to
monitor progression of the retinal changes.
The most frequent alterations observed were, by
decreasing order of frequency, RLA-leaking sites, areas
of increased retinal thickness and microaneurysms/
hemorrhages.
RLA-leaking sites were a very frequent ﬁnding and
reached very high BRB permeability values in some
eyes. These sites of alteration of the BRB, well identiﬁed
in RLA-maps, maintained, in most cases, the same
location on successive examinations, but their BRB
permeability values ﬂuctuated greatly between examina-
tions, indicating reversibility of this alteration (Fig. 7).There was, in general, a correlation between the BRB
permeability values and the changes in HbA1C levels
occurring in each patient. This correlation was particu-
larly clear when looking at eyes that showed, at some
time during the follow-up period, BRB permeability
values within the normal range. A return to normal
levels of BRB permeability was, in this study and in each
patient, always associated with a stabilization or
decrease in HbA1C values.
The frequent ﬁnding of RLA-leaking sites in these
14 eyes conﬁrms previous reports using ﬂuorescein
angiography (Wise et al., 1971), vitreous ﬂuorometry
(Cunha-Vaz et al., 1985a, b) and retinal leakage analysis
(Lobo et al., 1999), which show that alteration of
vascular permeability is one of the most frequent
alterations occurring in the initial stages of diabetic
retinal disease.
Areas of increased retinal thickness were another
frequent ﬁnding in these eyes. They were present in
every eye at some time during the follow-up and were
absent, at baseline, in only two of the 14 eyes. This
conﬁrms previous observations by our group (Lobo et
al., 1999) and by others (Fritsche et al., 2002).
However, the areas of increased retinal thickness
varied in their location over subsequent examinations
and did not correlate with changes in HbA1C levels.
They may represent a delayed response in time to other
changes occurring in the retina, such as increased
leakage, as suggested previously (Lobo et al., 1999).
The areas of increased retinal thickness may, indeed,
represent in most cases, zones of extracellular edema, an
interpretation supported by the frequent shift observed
in their location.
Increased rates of red-dot accumulation were found in
eyes that showed more red-dots at baseline and higher
values of BRB permeability during the study. By
combining different imaging techniques, multimodal
imaging of the macula made apparent three major
evolving patterns occurring during the follow-up period
of 3 years: Pattern A included eyes with reversible and
relatively little abnormal ﬂuorescein leakage, a slow rate
of microaneurysm formation and a normal FAZ. This
group appears to represent eyes presenting slowly
progressing retinal disease; Pattern B included eyes with
persistently high leakage values, indicating an important
alteration of the BRB, high rates of microaneurysm
accumulation and a normal FAZ. All these features
suggest a rapid and progressive form of the disease. This
group may identify a ‘‘wet’’ form of diabetic retino-
pathy, and; Pattern C included eyes with variable and
reversible leakage and an abnormal FAZ. This group is
less well characterized considering the small number of
eyes that showed an abnormal FAZ. It may be that
abnormalities of the FAZ may occur as a late
development of groups A and B or progress rapidly as
a speciﬁc ‘‘ischemic’’ form (table).
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Fig. 8. Schematic development of nonproliferative diabetic retino-
pathy leading to the three different patterns proposed: A, B and C.
Fig. 7. Multimodal images from with 0, 12, 24 and 36 (left to right) showing for each visit the FAZ—black contour—retinal leakage analyzer results
and retinal thickness analyzer results. The retinal leakage analyzer color-coded maps of the BRB permeability indexes are shown; retinal thickness
analyzer views show white dot density maps of the percentage increases in retinal thickness. Top row: pattern A. Note the little amount of retinal
leakage over the 4 represented visits and the normal FAZ contour. This patient showed a slow rate of microaneurysm formation. Middle row: pattern
B. Note the high retinal leakage showing a certain degree of reversibility and the normal FAZ contour. This patient showed a high rate of
microaneurysm accumulation over the 3-year follow-up period. Bottom row: pattern C. Note the reversible retinal leakage and the development of an
abnormal FAZ contour. This patient showed a high rate of microaneurysm formation.
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following for 2 years 59 patients with diabetes type 2
and mild NPDR. In this larger study these three
different phenotypes were again clearly identiﬁed. The
discriminative markers of these phenotypes were: red-
dot formation rate, measurements of ﬂuorescein leak-
age, signs of capillary closure in the capillaries
surrounding the FAZ and duration of diabetes.
It must be realized that levels of hyperglycemia and
duration of diabetes, i.e., exposure to hyperglycemia, are
expected to inﬂuence the evolution and rate of progres-
sion tentatively classiﬁed in these three major patterns
(Fig. 8).
If diabetic retinopathy is a multifactorial disease—in
the sense that different factors or different pathways
may predominate in different groups of cases with
diabetic retinopathy—then it is crucial that these
differences and the possible different phenotypes be
identiﬁed (Grange, 1995).
Diabetes mellitus is a familial metabolic disorder with
strong genetic and environmental etiology. Familial
aggregation is more common in type 2 diabetes than in
type 1 diabetes. Rema et al. (2002) reported that familial
clustering of diabetic retinopathy was three times higher
in siblings of type 2 subjects with diabetic retinopathy.
Presence or absence of genetic factors may play a
fundamental role in determining speciﬁc pathways of
vascular disease and, as a consequence, different
progression patterns of diabetic retinal disease. It couldbe that certain polymorphisms would make the retinal
circulation more susceptible to an early breakdown of
the BRB (type B) or microthrombosis and capillary
closure (type C). The absence of these speciﬁc genetic
polymorphisms would lead to an evolving pattern of
type A.
It is clear from this study and from previous large
studies such as the Diabetes Control and Complications
Trials group (DCCT) (2002), and UKPDS (Stratton
et al., 2001) that hyperglycemia plays a determinant role
in the progression of retinopathy. It is interesting to note
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Fig. 9. Representation of different patterns of progression of different
diabetic retinopathy phenotypes.
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(Snieder et al., 2001).
An interesting perspective of our observations,
analyzed under the light of available literature, depicts
diabetic retinopathy as a microvascular complication of
diabetes mellitus conditioned in its progression and
prognosis by a variety of different genetic polymorph-
isms, and modulated in its evolution by HbA1C levels,
partly genetically determined and partly dependent on
individual diabetes management. The interplay of these
multiple factors and the duration of this interplay would
ﬁnally characterize different clinical pictures or pheno-
types of diabetic retinopathy (Fig. 9).
The ultimate goal, therefore, should be the character-
ization of relationships between genetic factors (repre-
sented by distinct genotypes) and their medically
signiﬁcant expression (distinct diabetic retinopathy
phenotypes). Our observations of a 3-year prospective
study of eyes with mild nonproliferative diabetic
retinopathy of patients with type 2 diabetes mellitus,
suggest three different phenotypes of diabetic retino-
pathy: a ‘‘wet’’ or ‘‘leaky’’ type, an ‘‘ischemic’’ type, and
ﬁnally, an apparently more common, slow progression
type.4. Directions for future work
4.1. Candidate phenotype/genotype correlations
It is recognized that polymorphic variability in the
genetic make-up of an individual can profoundly
inﬂuence the expression of a gene and its response to
environmental factors. As we predict that the impact of
single common mutations on RD development will be
modest (increasing relative risk (RR) by 20–40% at
most), the main issue of clinical relevance is whether the
conferred risk of such a mutation is very much higher in
some population subgroups. To be clinically useful in arisk algorithm we might require for any factor to have a
RR of 2 or greater (Humphries et al., 2001).
Such subgroups might be those carrying a second
important mutation in another gene and such indivi-
duals might be identiﬁed using conventional genetic
strategies. Alternatively, one might identify individuals
exposed to a given environment which ampliﬁes the risk
associated with that gene (i.e., gene–environment inter-
action).
Diabetic retinopathy shows familial aggregation and
variation in disease severity which is not explained by
environmental, biochemical or biological risk factors
alone.
There are substantial variations in onset and severity
of retinopathy in different patients which are indepen-
dent of the duration of diabetes and level of glycemic
control.
A relatively large number of candidate genes have
been examined in patients with diabetes but clear
genotype–phenotype associations have not yet been
identiﬁed.
One of the major problems is associated with poor
characterization of different retinopathy phenotypes. It
is fundamental before embarking in a search for
candidate genes to deﬁne clinical phenotypes character-
ized by speciﬁc patterns of severity and progression of
DR. It is clear that it is necessary to identify ﬁrst and
well the DR phenotypes that are associated with rapid
progression of the retinopathy to severe forms of the
disease, such as macular edema and proliferative
retinopathy. Only then, studies on candidate genes are
worth pursuing, involving appropriately well-deﬁned
subgroups of patients (Warpeha and Chakravarthy,
2003).
There are several physiological systems that are
involved in maintaining retinal vascular health and
disease can be predicted to develop resulting from a
failure to maintain hemostasis. One, is the endothelial
lining of the vessel wall with its role in maintaining the
BRB, inﬂuencing vessel tone, maintaining normal wall
structure and preventing thrombosis. Another, is the
coagulation cascade. Other possibilities include the
normal homeostatic systems which regulate short-term
blood pressure and plasma and intracellular lipid
metabolism.
Variations in the genes expressed in the aldose
reductase pathway may inﬂuence microvascular suscept-
ibility. Aldose reductase is strongly expressed in retinal
pericytes and is also found in the vascular endothelium
(Vino˜res et al., 1993). It has been suggested that 7q35 is
a susceptibility region for diabetic retinopathy by virtue
of the aldose-reductase gene (AR2) (Patel et al., 1996).
In type 1 diabetes the strongest genetic risk compo-
nent is localized within the major histocompatibility
complex. The HLA region that is located on 6p21, has
also been implicated as genomic region of interest for
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et al., 1993) and type 2 diabetes (Serrano-Rios et al.,
1983).
Glut transporter genes have been examined but no
association between polymorphisms in the Glut 1 gene
and retinopathy status was found.
Other candidate genes involved in cell communication
and the extracellular communication have also been
investigated without conclusive data (Warpeha and
Chakravarthy, 2003). These authors and their group
have paid special attention to the genes of endothelins
(ET) and nitric oxide synthases (NOS). NOS and ET are
counter regulatory and the NO/ET pathway is crucial to
maintain the tone of the vasculature, which is delicately
controlled by the balance in their expression. They
identiﬁed microsatelite polymorphic markers in mem-
bers of ET and NOS families as well as those of
endothelin converting enzyme (ECE1).
Subjects with no retinopathy despite 15 years or more
of diabetes (controls) and any subject with severe
retinopathy regardless of duration (ETDRS level 50 or
worse) were prospectively recruited into these studies.
None of the polymorphisms studied in the NOS 1 or
NOS 3 genes was signiﬁcantly associated with cases or
controls. However, studies on the NSO2A gene showed
that a 14-repeat allele of a pentanucleolide polymorph-
ism in the 50UTR of NOS2A gene was protective against
developing diabetic retinopathy in both patient popula-
tions (Warpeha et al., 1999). The authors suggest that
when NOS3 expression is low in the diabetic retina
induction of NOS2A may occur in an attempt to achieve
homeostasis (Graier et al., 1993), possibly playing a
crucial role in preventing or delaying pathological
alterations in the microcirculation in diabetes.
There are indications that the vascular complication
of diabetes are related with the formation of advanced
glycated-end products (AGE). The glycation of proteins
and lipids is a result of hyperglycemia and this effect of
AGEs is mediated the AGE receptor (RAGE) which is
regulated by a gene (Hudson et al., 2001).
Angiotensin-converting enzyme (ACE) is another
important mediator of vasoconstriction and home-
ostasis; however, studies to date on genetic markers of
members (Matsumoto et al., 2000) of this signaling
pathway have not shown deﬁnitive evidence of direct
genetic risk. It remains, however, an interesting candi-
date gene to play a role in DR. Clinical studies have
shown that ACE inhibition may play a useful speciﬁc
role in the management of DR.
Large interindividual differences in plasma ACE
levels exist but are similar within families, suggesting a
strong genetic inﬂuence. The human ACE gene is found
on chromosome 17 and contains a restriction fragment
length polymorphism consisting of the presence (inser-
tion, I) or absence (deletion, D) of a 287 base pair
‘‘ALU’’ repeat sequence in intron 16 (Rigat et al., 1990).In 1992, the I/D polymorphisms of the ACE gene were
reported to be associated with risk of myocardial
infarction (Cambien et al., 1992) and this effect, though
more modest then originally reported has been con-
ﬁrmed in larger studies (Keavney et al., 2000).
Glucose may itself be the mitigating environmental
factor that induces expression of the polymorphism.
The situation on a complex and multifactorial disease
such as diabetes favors the presence of gene–environ-
ment interactions. A key factor in the identiﬁcation and
study of gene–environment interaction is that an
individual carrying such a mutation will develop the
phenotype only if and when they enter the high risk
environment. Thus, the mutation will cause a speciﬁc
retinal vascular alteration, i.e., alteration of BRB or
blood-ﬂow changes in the presence of a speciﬁc
environmental challenge. This classical ‘‘lack of pene-
trance’’ of a mutation will cause analytical problems and
mis-phenotyping which will be particularly problematic
with some sampling analytical designs. This ‘‘content-
dependency’’ of a mutation (i.e., gene X environment
effect) must be taken into consideration when analyzing
associations between a candidate gene polymorphism
and intermediate phenotypes.
Most of the results published indicate the presence of
genetic determinants for resistance or susceptibility to
vascular complications. However, there is evidence of
problems in replicating results suggesting that the
studies performed have been plagued with confounding
factors.
The results of our research group on the character-
ization of different phenotypes of DR conﬁrm that there
are distinct morphological manifestations in DR with
different subjects presenting different rates of progres-
sion and different evolution patterns. (Lobo et al.,
2004). There is, now, evidence indicating that suscept-
ibility to the late vascular complications of diabetes,
such as retinopathy, depend, at least partly, on genetic
factors (Wasgenknecht et al., 2001).
The risk of severe DR in the siblings of affected
individuals is substantially increased (Leslie and Pyke,
1982). It is possible that the problems associated with
identifying susceptibility genes for diabetic retinopathy
is due mainly to the still accepted view that diabetic
retinopathy is one uniform and homogenous disease.
Speciﬁc types of more severe retinopathy may need to be
identiﬁed before progress is achieved in this area of
research.
Another factor that must be taken into consideration
is duration of diabetes. Problems encountered may be
minimized by selecting case subjects with short diabetes
duration and control subjects with larger duration, or by
adjusting to duration during analysis.
It is clear that future studies should focus on the need
to characterize more accurately different phenotypes
with respect to retinopathy status. We agree entirely
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that agreed international standards for data collection,
particularly agreement on a minimum data set for the
phenotyping of retinopathy in subjects with diabetes,
would permit the pooling of data from the many studies
with enhanced power to detect associations.
A classiﬁcation of diabetic retinopathy based on both
relevant genotypes and disease phenotypes is an
ambitious goal. We believe that this route may help
identify the particular form that threatens an individual
patient and consequently offer an opportunity for
speciﬁc and more effective therapies.
4.2. Relevance for clinical trial design
Studies such as the Diabetes control and complica-
tions trial (Diabetes control and complications trial
Group, 2002), the United Kingdom prospective diabetes
study (United Kingdom Prospective Diabetes Study,
1998), the diabetic retinopathy study research group
(Diabetic Research Study Research Group, 1981) and
the early treatment diabetic retinopathy study (Early
Treatment Diabetic Retinopathy Study, 1991) validated
methods now considered standard in treating diabetic
retinopathy when it occurs, i.e., tight control of blood
glucose levels to prevent retinopathy and laser photo-
coagulation to halt progression after development of
CSME or proliferative retinopathy. However, despite
the aim of tight blood glucose control and the use of
retinal photocoagulation, blindness still occurs. Other
forms of therapy targeted at the earliest stages of retinal
disease, involving necessarily the demonstration of
efﬁcacy of a new drug are urgently needed and remain
a priority for eye research.
One of the major problems lies in the limitations that
characterize at present the accepted methods of retino-
pathy assessment, visual acuity changes and fundus
photography. Visual acuity changes are detected too late
in the course of the disease and fundus photography, as
it has been used, in descriptive manner, is subjective and
has been unable to characterize progression in the initial
stages of the retinopathy. To make things more difﬁcult
it is well known that the course of retinopathy is not
linear and lesions that appear on fundus photography
may come and go. Apparent clinical improvement on
fundus photography may, in reality, mask worsening of
the disease.
It is crucial in order to design an appropriate clinical
trial to test the efﬁcacy of a drug, to identify not only the
meaningful clinical endpoints but also the surrogate
endpoints that may demonstrate efﬁcacy of a drug in a
realistic and feasible period of time (Cunha-Vaz, 2000b).
Approval of a drug to treat diabetic retinopathy must
take into account that it must appeal to clinicians as
being useful to their patients, which means that it must
show efﬁcacy to clinical endpoints that they can see intheir patients and recognize ‘‘this is the patient I would
use that therapy for’’.
It must be taken into account that the clinicians must
understand what the drug is being used for and in which
group of patients, so that they can explain the potential
risks and beneﬁts to their patients.
It is immediately clear that such process implies the
validation of surrogate endpoints by the associated
occurrence of hard clinical outcomes such as signiﬁcant
visual loss. It is here that the problem lies. Diabetic
retinopathy progresses to irreversible stages of the
disease with relatively little visual loss, and when
macular edema or proliferative retinopathy are present,
it becomes ethically mandatory to perform photocoa-
gulation treatment.
The development of an effective drug must take into
account the need to demonstrate efﬁcacy on the earliest
and reversible stages of diabetic retinal disease by
demonstrating its effect on surrogate endpoints which
can be followed for shorter periods of time. The
assumption would be that those surrogate endpoints
would ultimately be validated by association with more
hard clinical outcomes, but that should not necessarily
need to occur before provisional approval.
It is therefore an urgent priority to identify end-
points which people can accept as surrogates that are
expected to be later validated in longer natural history
studies.
The clinical endpoints that have been accepted in the
past are: mean difference between groups in visual
acuity of at least 3 lines in a ETDRS-Type chart, i.e.,
doubling of the visual angle; mean difference in visual
ﬁeld of at least 10 dB; reduction in percentage of patients
with vitreous hemorrhage; reduction in percentage of
patients with rubeosis; reduction in occurrence of retinal
detachments, and need for photocoagulation treatment
according to DRS and ETDRS guidelines (DRS, 1981;
ETDRS, 1991). All of these are what may be called
terminal endpoints. They only give indications about the
late, irreversible, stages of diabetic retinopathy.
The candidates for surrogate endpoints in the initial
stages of the retinal disease are not many: mean
differences on the ETDRS retinopathy scale, reduction
in ﬂuorescein leakage, reduction in macular thickening
and red-dot (microaneurysms/hemorrhages) counting.
The problem of using the ETDRS retinopathy scale
lies in the fact that in the initial stages of the retinopathy
even a two-step eye change means that we have to wait
for an important worsening of the retinopathy and the
presence of irreversible changes.
The second possibility, reduction in ﬂuorescein
leakage, measures one of the two main factors in the
progression of the retinopathy, the alteration of the
BRB permeability which is quantitative, allowing for
precise evaluation of progression. It has, however, a
major drawback, it involves ﬂuorescein administration
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a reliable test involving oral ﬂuorescein administration.
The third candidate, reduction in macular thickening
by measuring the mean change with dedicated instru-
mentation, is a promising alternative. The measure-
ments are reliable, and changes in retinal thickness
are a direct indication of macular edema (Shahidi et al.,
1994; Hee et al., 1995). The problem associated with
this outcome lies in the variability of the evolution
of macular edema and in the fact that macular edema
is only one of the manifestations of diabetic retinal
disease.
Finally, the fourth possibility, red-dot counting on
fundus photographs, taking into account every new
microaneurysms/hemorrhage according to their exact,
speciﬁc location in the eye fundus is noninvasive and has
the potential to become an extremely informative
marker of the overall progression of diabetic retinal
vascular disease. The rate of formation of new red-dots
appears to be a direct indication of the progression of
retinal vascular damage and is statistically correlated
with the progression in ﬂuorescein leakage, i.e., the
alteration of the BRB and capillary closure (Torrent-
Solans et al., 2003). By counting red-dots on digitalized
fundus photographies, using appropriate software to
identify the speciﬁc location of each red-dot, we may be
able to measure the rate of progression of the two major
factors in diabetic vascular retinal disease: vascular
hyperpermeability and capillary closure.
It is crucial and urgent now to validate the last two
candidates for surrogate endpoints, retinal thickness
measurements and/or red-dot formation rates both
using noninvasive methodologies. Their use and ﬁnal
validation are expected to contribute decisively to design
clinical trials to test the efﬁcacy of new drugs capable of
halting diabetic retinal disease in the initial stages of the
disease. Another fundamental step in this procedure is
the characterization of the different phenotypes of
diabetic retinal disease.
The design of future clinical trials should consider
only groups of patients characterized by their homo-
geneity: patients presenting a speciﬁc retinopathy
phenotype (wet/leaky or ischemic), with similar duration
of diabetes and at similar levels of blood pressure and
metabolic control (HbA1C values).4.3. Relevance for clinical management
It is accepted that in the initial stages of diabetic
retinopathy when the fundus alterations detected by
ophthalmoscopy or slit-lamp examination are limited to
red-dot and hard or soft exudates, i.e., mild or
nonproliferative DR, an annual examination is indi-
cated to every patient with ﬁve or more years of
duration of their diabetes.This is the recommendation of the American Acad-
emy of Ophthalmology Guidelines for Diabetic Retino-
pathy (Fong and Ferris, 2003).
Our observations and the identiﬁcation of different
diabetic retinopathy phenotypes in the initial stages of
DR, i.e., mild or moderate NPDR, characterized by
different rates of progression of the retinopathy suggest
that speciﬁc approaches should be used when managing
these different retinopathy phenotypes.
A patient with mild or moderate NPDR, presenting
retinopathy phenotype B (wet/leaky), characterized by
marked breakdown of the BRB, identiﬁed by highly
increased values of ﬂuorescein leakage into the vitreous
and a high red-dot formation rate, registered during a
period of 1–2 years of follow-up, indicating fast
retinopathy progression, should be watched more
closely and examined at least at 6 months intervals.
Furthermore, blood pressure values and metabolic
control should be closely monitored at least at 3-month
intervals and medication given to keep HbA1c levels at
p7.1%, systolic blood pressure at p140mmHg and
diastolic blood pressure at p85mmHg. Communi-
cation channels should be rapidly established between
ophthalmologist and their diabetologist, internist or
general health care provider. Information should
be given indicating that the chances of rapid retino-
pathy progression to more advanced stages of disease
are in these patients relatively high, calling for im-
mediate tighter control of both glycemia and blood
pressure.
A patient with mild or moderate nonproliferative
diabetic retinopathy presenting retinopathy phenotype
C, ischemic, characterized by clear signs of capillary
closure and variable red-dot formation rates would
similarly indicate the need for shorter observation
intervals than one year with particular attention for
other systemic signs of microthrombosis. Here, however,
control of hyperglycemia and blood pressure must be
addressed with some degree of caution. Improved
metabolic and blood pressure control must be progres-
sive and less aggressive than with phenotype B. It is
realized that the ischemia that characterizes phenotype
C may become even more apparent in eyes submitted to
rapid changes in metabolic control and lowering rapidly
the blood pressure may increase the retinal damage
associated with ischemia.
Finally, a patient with mild or moderate NPDR,
presenting phenotype A, identiﬁed by low levels of
ﬂuorescein leakage, no signs of capillary closure, low
red-dot formation rates and with a diabetes duration of
more than 10 years, all signs indicating a slowly
progression subtype of diabetic retinopathy may be
followed at intervals longer than one year. If the
examination performed at two years intervals conﬁrms
the initial phenotype characterization, the patient and
his diabetologist, internist or general health care
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associated with this retinopathy phenotype.
4.4. Targeted treatments
It would be of great beneﬁt to have a drug available
which would prevent the need for photocoagulation and
particularly one which may remove the other variables
that remain a cause of concern. So many of these
patients are not well controlled, they do not come to the
doctor often, and they are going blind because they do
not get medical attention in time for photocoagulation.
The major large clinical trials have shown that tight
glycemic control slows the development and progression
of diabetic retinopathy. But the constantly increasing
incidence of type 2 diabetes and the evidence that retinal
damage begins early on, underscore the need for a
medical treatment that is targeted to the initial retinal
alterations and to speciﬁc phenotypes of the retinal
diabetic disease.
Several key pathways have been incriminated in the
process of triggering diabetic retinal disease and they
may play speciﬁc roles in the development of speciﬁc
retinopathy phenotypes. Four candidates, the polyol
pathway, nonenzymatic glucosylation, growth factors
and protein-kinase C, may be playing leading roles in
the development of diabetic retinal disease.
The polyol pathway theory holds that increased
glucose metabolism, through the enzyme aldose–reduc-
tase interferes with sodium–potassium ATPase, dama-
ging the retina (Greene et al., 1987).
The nonenzymatic glycosylation theory holds that the
bonding of sugar molecules to other reactive molecules
leads to critical retinal alterations and enhancement of
processes of oxidative stress to the retina (Brownlee,
1994).
In the growth factor hypothesis, diabetes-induced
damage promotes the liberation of growth factors that
appear clearly as the best candidates to explain the
developments of proliferative retinopathy. However, the
potential role of growth factors in the initial stages and
in nonproliferative retinopathy remains highly hypothe-
tical (Clermont et al., 1997).
Finally, the protein kinase C theory. Many of the
metabolic changes associated with hyperglycemia-in-
duced oxidative stress, advanced glycosylation end-
products of diacylglycerol through the polyol pathway,
ultimately activate protein kinase C. In the retina, there
is evidence that activation of the beta-isoform of PKC
(PKC-beta) is associated with retinal vasodilatation and
alterations in retinal blood ﬂow, thus making PKC-beta
an obvious target for intervention (Ishii et al., 1996).
A role for inﬂammation has also been proposed, and
inﬂammation mediators have been suggested to be
responsible for the increased ﬂuorescein leakage ob-
served in the initial stages of diabetes, by causingalterations in the tight junctions of the retinal vessels
(Antonetti et al., 1998).
It is possible that all these different mechanisms of
disease play complementary roles in the progression of
diabetic retinal disease.
The identiﬁcation of different retinopathy phenotypes
characterized by different rates of progression and
different dominant retinal alterations, may indicate
that different disease processes predominate in speci-
ﬁc retinopathy phenotypes, probably determined by
speciﬁc gene mutations.
Individuals with a speciﬁc gene mutation which makes
them more susceptible to the abnormal metabolic
environment of diabetes will respond by developing a
speciﬁc retinopathy phenotype.
Identiﬁcation of well-deﬁned retinopathy phenotypes
appears to be an essential step in the quest for a
successful treatment of diabetic retinopathy. After the
characterization of speciﬁc retinopathy phenotypes, the
predominant disease mechanisms involved may be
identiﬁed and drugs directly targeted at the correction
of these disease mechanisms used with greater chances
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